My research background is in haematopoiesis, arthritis and macrophage-lineage cell biology.

My current research focuses on mechanisms of disease, and identifying biomarkers that predict disease and response to treatment.

Felix Clanchy

PhD, LLB

Postdoctoral Researcher

Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF+ T Lymphocytes.
Journal article

Bystrom J. et al, (2017), Clin Rev Allergy Immunol, 53, 265 - 276
CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease.
Journal article

Borghese F. and Clanchy FIL., (2011), Expert Opin Ther Targets, 15, 237 - 251
The development of macrophages from human CD34+ haematopoietic stem cells in serum-free cultures is optimized by IL-3 and SCF.
Journal article

Clanchy FIL. and Hamilton JA., (2013), Cytokine, 61, 33 - 37
High-Affinity Fc Receptor Expression Indicates Relative Immaturity in Human Monocytes.
Journal article

Clanchy FIL., (2016), J Interferon Cytokine Res, 36, 279 - 290
Ibudilast Inhibits Chemokine Expression in Rheumatoid Arthritis Synovial Fibroblasts and Exhibits Immunomodulatory Activity in Experimental Arthritis.
Journal article

Clanchy FIL. and Williams RO., (2019), Arthritis Rheumatol, 71, 703 - 711
Targeting early changes in the synovial microenvironment: a new class of immunomodulatory therapy?
Journal article

Aungier SR. et al, (2019), Ann Rheum Dis, 78, 186 - 191

TNFα inhibitors reduce bone loss in rheumatoid arthritis independent of clinical response by reducing osteoclast precursors and IL-20
Journal article

Al-Bogami M. et al, (2020), Rheumatology
Response to: 'Potential roles for tenascin in (very) early diagnosis and treatment of rheumatoid arthritis' by Cutolo et al.
Journal article

Aungier S. et al, (2020), Ann Rheum Dis, 79

More publications